ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Naoko OkuraNaoya NishiokaTadaaki YamadaHirokazu TaniguchiKeiko TanimuraYuki KatayamaAkihiro YoshimuraSatoshi WatanabeToshiaki KikuchiShinsuke ShiotsuTakeshi KitazakiAkihiro NishiyamaMasahiro IwasakuYoshiko KanekoUchino JunjiHisanori UeharaMano HorinakaToshiyuki SakaiKohei TanakaRyohei KozakiSeiji YanoTakayama KoichiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These results demonstrate that ONO-7475 suppresses the emergence and maintenance of tolerant cells to the initial EGFR-TKIs, osimertinib or dacomitinib, in AXL-overexpressing EGFR-mutated NSCLC cells, suggesting that ONO-7475 and osimertinib is a highly potent combination for initial treatment.